1.
Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases
by Akdis, Mübeccel, MD, PhD
Journal of allergy and clinical immunology, 2016, Vol.138 (4), p.984-1010
2.
Adaptive immune features of natural killer cells
by Lanier, Lewis L
Nature, 2009-01-29, Vol.457 (7229), p.557-561
3.
The effect of maternal antibodies on the cellular immune response after infant vaccination: A review
by Orije, Marjolein R.P
Vaccine, 2020-01-03, Vol.38 (1), p.20-28
4.
Immunoinformatics approaches to design a novel multi-epitope subunit vaccine against HIV infection
by Pandey, Rajan Kumar
Vaccine, 2018-04-19, Vol.36 (17), p.2262-2272
5.
Identification of preexisting adaptive immunity to Cas9 proteins in humans
by Charlesworth, Carsten T
Nature medicine, 2019-02, Vol.25 (2), p.249-254
6.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
by Ewer, Katie J
Nature medicine, 2021-02, Vol.27 (2), p.270-278
7.
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
by Feldman, Robert A
Vaccine, 2019-05-31, Vol.37 (25), p.3326-3334
8.
Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseases
by Akdis, Mübeccel, MD, PhD
Journal of allergy and clinical immunology, 2011, Vol.127 (3), p.701-721.e70
9.
10.
Humoral immune response to Q fever vaccination of three sheep flocks naturally pre-infected with Coxiella burnetii
by Bauer, Benjamin U
Vaccine, 2021-03-05, Vol.39 (10), p.1499-1507
11.
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
by Gruell, Henning
Nature medicine, 2022-03, Vol.28 (3), p.477-480
12.
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
by Apostolidis, Sokratis A
Nature medicine, 2021-11, Vol.27 (11), p.1990-2001
13.
Immunogenicity of Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine Expressing Glycoprotein from the 2014 Epidemic Strain in Mice
by Wang, Ling
Human gene therapy, 2018-01-01, Vol.29 (1), p.87-95
14.
Delayed production of neutralizing antibodies correlates with fatal COVID-19
by Lucas, Carolina
Nature medicine, 2021-07, Vol.27 (7), p.1178-1186
15.
Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates
by Monslow, Morgan A
Vaccine, 2020-08-10, Vol.38 (36), p.5793-5802
16.
A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18–49 year old patients
by Racine, Étienne
Vaccine, 2020-09-11, Vol.38 (40), p.6205-6214
17.
Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge
by Lopes, Priscila Diniz
Vaccine, 2018-05-03, Vol.36 (19), p.2630-2636
18.
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
by Colonna, Marco
Nature, 2009-02-05, Vol.457 (7230), p.722-725
19.
Immunogenicity study of engineered ferritins with C- and N-terminus insertion of Epstein-Barr nuclear antigen 1 epitope
by Qu, Yiran
Vaccine, 2021-08-09, Vol.39 (34), p.4830-4841
20.
The vagal innervation of the gut and immune homeostasis
by Matteoli, Gianluca
Gut, 2013-08, Vol.62 (8), p.1214-1222
